New Insight into Parkinson’s Spread: The mGluR4-NPDC1 Complex Identified

Parkinson’s disease, a neurodegenerative disorder marked by tremor, bradykinesia, and balance loss, affects roughly 1.1 million Americans with ? 90,000 new diagnoses each year. The pathological hallmark is the accumulation of misfolded ?-synuclein, a protein that can propagate between neurons, worsening motor symptoms. Understanding how ?-synuclein moves across cells is essential for developing disease-modifying therapies.

SciTechDaily

Researchers at Yale School of Medicine screened 4,400 engineered cell lines, each expressing a distinct neuronal surface protein, for binding to misfolded ?-synuclein. Only 16 proteins showed affinity; among them, mGluR4 and NPDC1—both naturally present on dopamine-producing neurons in the substantia nigra—were found to ferry ?-synuclein into healthy cells. This suggests a receptor-mediated entry route previously unrecognized in Parkinson’s pathology.

SciTechDaily

To test causality, the team generated mice lacking functional mGluR4 or NPDC1 and introduced misfolded ?-synuclein. In wild-type controls, the protein accumulated, producing Parkinson-like motor deficits and elevated mortality. Knockout mice displayed significantly reduced ?-synuclein buildup, slower symptom progression, and lower risk of death. The parallel reduction in both proteins indicates they act cooperatively to mediate neurodegeneration.

SciTechDaily

• 1.1 million U.S. patients living with Parkinson’s.

SciTechDaily

• ? 90,000 new U.S. cases annually.

SciTechDaily

• 4,400 cell-surface-protein variants screened.

SciTechDaily

• 16 proteins bound misfolded ?-synuclein; 2 (mGluR4, NPDC1) were functional mediators.

SciTechDaily

• Genetic removal of either protein in mice mitigated disease markers and improved survival.

SciTechDaily

Senior author Stephen Strittmatter, MD, PhD, emphasized that the findings reveal a “possible new route for Parkinson’s disease treatment.” He noted that existing medications “mainly help manage symptoms, but they do not effectively stop the disease from progressing.” The work was funded by the Michael J. Fox Foundation (grant 16257) and multiple NIH grants (R01AG034924, R35NS097283, R01AG070926, R01AG066165, P30AG066508).

SciTechDaily

Targeting the mGluR4-NPDC1 complex could shift therapeutic strategies from symptom relief to directly halting ?-synuclein spread, a critical step as the U.S. population ages. Slowing neuronal loss may reduce long-term disability and health-care burden associated with Parkinson’s and related neurodegenerative disorders.

SciTechDaily

While the mouse data are compelling, the precise role of mGluR4 and NPDC1 in human ?-synuclein transmission remains unverified. Further studies are needed to confirm whether blocking these receptors can safely and effectively impede disease progression in patients.

SciTechDaily

• “If we understood how it gets into neurons, we could perhaps block or slow down the progression of the disease,” — Stephen Strittmatter, MD, PhD, Senior Author

SciTechDaily

• “Misfolded ?-synuclein is “the pathologic hallmark of Parkinson’s disease,” he says.” — Stephen Strittmatter

SciTechDaily

• “We have an aging population. How we can stop or slow neurons from dying is an enormous problem,” — Stephen Strittmatter

SciTechDaily

• “This is really the time to make some inroads into figuring out how to slow it down.” — Stephen Strittmatter

SciTechDaily

The research team plans to validate the mGluR4-NPDC1 pathway in human neuronal cultures, screen for small-molecule inhibitors, and initiate preclinical safety studies. Successful translation could lead to the first disease-modifying therapy that directly interferes with ?-synuclein propagation.

SciTechDaily